Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate ... - UroToday
Bayer will present new prostate cancer data, including a Phase III ARANOTE trial analysis of NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC), at the ESMO Congress 2024 in Barcelona.
Reference News
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate ... - UroToday
Bayer will present new prostate cancer data, including a Phase III ARANOTE trial analysis of NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC), at the ESMO Congress 2024 in Barcelona.